Interleukin-17F Has Anti-Tumor Effects in Oral Tongue Cancer

Show full item record



Almahmoudi , R , Salem , A , Murshid , S , Dourado , M R , Apu , E H , Salo , T & Al-Samadi , A 2019 , ' Interleukin-17F Has Anti-Tumor Effects in Oral Tongue Cancer ' , Cancers , vol. 11 , no. 5 , 650 .

Title: Interleukin-17F Has Anti-Tumor Effects in Oral Tongue Cancer
Author: Almahmoudi, Rabeia; Salem, Abdelhakim; Murshid, Sakhr; Dourado, Mauricio Rocha; Apu, Ehsanul Hoque; Salo, Tuula; Al-Samadi, Ahmed
Contributor organization: Department of Oral and Maxillofacial Diseases
TRIMM - Translational Immunology Research Program
Research Programs Unit
HUS Internal Medicine and Rehabilitation
Date: 2019-05
Language: eng
Number of pages: 13
Belongs to series: Cancers
ISSN: 2072-6694
Abstract: We recently showed that extracellular interleukin-17F (IL-17F) correlates with better disease-specific survival in oral tongue squamous cell carcinoma (OTSCC) patients. However, the underlying mechanisms of such effect remain obscure. Here, we used qRT-PCR to assess the expression of IL-17F and its receptors (IL-17RA and IL-17RC) in two OTSCC cell lines (HSC-3 and SCC-25) and in normal human oral keratinocytes (HOKs). IL-17F effects on cancer cell proliferation, migration, and invasion were studied using a live-imaging IncuCyte system, and a Caspase-3/7 reagent was used for testing apoptosis. 3D tumor spheroids were utilized to assess the impact of IL-17F on invasion with or without cancer-associated fibroblasts (CAFs). Tube-formation assays were used to examine the effects of IL-17F on angiogenesis using human umbilical vein endothelial cells (HUVEC). OTSCC cells express low levels of IL-17F, IL-17RA, and IL-17RC mRNA compared with HOKs. IL-17F inhibited cell proliferation and random migration of highly invasive HSC-3 cells. CAFs promoted OTSCC invasion in tumor spheroids, whereas IL-17F eliminated such effect. IL-17F suppressed HUVEC tube formation in a dose-dependent manner. Collectively, we suggest that IL-17F counteracts the pro-tumorigenic activity in OTSCC. Due to its downregulation in tumor cells and inhibitory activity in in vitro cancer models, targeting IL-17F or its regulatory pathways could lead to promising immunotherapeutic strategies against OTSCC.
Subject: interleukin-17F
cancer immunotherapy
cytokine therapy
tongue cancer
oral squamous cell carcinoma
HUVEC cells
3122 Cancers
3125 Otorhinolaryngology, ophthalmology
3111 Biomedicine
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
cancers_11_00650.pdf 2.118Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record